Clinical Trial

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

Study acronym: AERON-1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo looks the drug but contains no medicine. Subjects will attend the clinic for complete general health checks and to complete questionnaires.
Protocol Amendment History 3 changes
notable Trial sites expanded: 17 -> 22 locations 2026-08-13
notable Trial sites expanded: 11 -> 17 locations 2026-07-31
notable Trial sites expanded: 2 -> 11 locations 2026-07-19
Trial Details
NCT Number NCT07610473
Lead Sponsor Draig Therapeutics Ltd
Conditions Major Depressive Disorder (MDD)
Enrollment 118 participants
Start Date 2026-05-14
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-12